News
-
-
-
COMMUNIQUÉ DE PRESSE
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
Veno Medical Corporation presents positive interim data on VenoValve for venous ulcer healing at Society for Vascular Surgery meeting. Company aims for FDA approval in Q4 2024 -
-
-
COMMUNIQUÉ DE PRESSE
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
enVVeno Medical Corporation to present new interim venous ulcer healing data from VenoValve U.S. trial at VAM2024. Study focuses on treatment of venous disease with innovative bioprosthetic solutions -
-
-
COMMUNIQUÉ DE PRESSE
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
enVVeno Medical Corporation reported ending the quarter with $42.9 million cash and investments to fund operations through 2025, presenting positive data at the 46th Annual Charing Cross Symposium -
